RVP

Retractable's income statement describes a business that no longer makes money on the products it sells. FY2025 gross profit was just $47K on $38.3M of revenue — a 0.1% gross margin — meaning cost of goods effectively equals sales before a dollar of overhead. Operating income was -$21.2M (-55.3% margin) and net income -$12.6M, the fourth consecutive year of deterioration since the COVID windfall collapsed (revenue fell from $188M in 2021 to $33M in 2024, with FY2025's +15.8% rebound to $38.3M still leaving the company deeply unprofitable). Revenue growth off a tiny, unprofitable base is not a thesis when every incremental unit is sold at cost.

The filing makes the cause explicit and structural: 62.6% of products are sourced from China, and as of March 2026 the prevailing tariff on syringes and needles from China is 120% (a 100% Section 301 duty that the Supreme Court's IEEPA ruling left untouched, plus a new 10% Section 122 duty). Roughly $1.8M of tariff expense hit 2025, and management states tariffs are 'expected to have a continuing material impact.' The mitigation — reshoring 0.5mL/1mL/3mL and EasyPoint production domestically — is only expected to reach commercial quantities in 2H2026, and management has already resorted to reductions in force in Q2/Q3 2025. This is a company fighting for survival against its own cost structure.